Skip to main content

Table 6 Mean scores of performance status

From: Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial

ECOG

Karnofsky

 

Number

mean ± standard division

SE

P-value

mean ± standard division

SE

P-value

Baseline

Placebo

14

1.7 ± 0.4

0.11

0.9

67.14 ± 6.1

1.6

0.9

Bupropion

13

1.7 ± 0.4

0.11

 

66.9 ± 8.5

2.3

 

End of 2nd week

Placebo

14

1.7 ± 0.4

0.11

0.3

67.1 ± 6.1

1.6

0.5

Bupropion

13

1.6 ± 0.5

0.14

 

69.2 ± 9.5

2.6

 

End of 6th week

Placebo

14

1.6 ± 0.5

0.13

0.001>

70 ± 9.6

2.5

0.01

Bupropion

13

0.9 ± 0.27

0.7

 

79.2 ± 7.5

2.1

Â